Aerie Pharma (AERI) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. SPY
5. META
6. INTC
7. NVDA
8. AAPL
9. JBLU
10. ANT

Go back to Aerie Pharma (AERI) Reports In-Line Q3 EPS

Aerie Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

November 2, 2016 4:01 PM EDT

- New Data Adds Further Positive Insight into RhopressaTM and RoclatanTM Potential -

- Company Closes the Third Quarter with Over $255 million in Cash and Investments -

Conference Call and Webcast Today, November 2, at 5:00 p.m. ET

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2016,... More